Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Table 2 Response according to mutational status

	KRAS exon 2 wt vs. mt	RAS wt vs. mt	PIK3CA/BRAF wt vs. mt	RAS/PIK3CA/BRAF All wt vs. any mt
Responder (n)	23 vs. 17	21 vs. 19	38 vs. 2	18 vs. 22
Non-responder (n)	19 vs. 18	15 vs. 21	31 vs. 5	10 vs. 26
ORR (%)	54.8 vs. 48.6	58.4 vs. 47.5	55.1 vs. 28.6	64.3 vs. 45.9
Difference in ORR	6.8	10.9	26.5	18.4
P value*	0.651	0.368	0.246	0.155

Responder, CR + PR; Non-responder, SD + PD + NE; ORR, overall response rate; wt, wild-type; mt, mutant
*calculated using Fisher’s exact test

ISSN: 1471-2407